Faqja 1 nga 16 rezultatet
The present invention relates to galactosylated pro-drugs of non-steroidal anti-inflammatories with free acid function and the process of synthesis thereof, which enables minimization of the gastrointestinal toxicity of the starting anti-inflammatory by means of esterification of its carboxylic
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to the fields of inflammation and carbohydrate and glycoprotein chemistry. More specifically, the present invention relates to novel disaccharide inhibitors of inflammation.
2. Description of the Related
BACKGROUND
1. Field of the Invention
The present invention relates to 3,6-anhydro-L-galactose prepared through chemical and enzymatic methods and industrial use thereof using physiological efficacy.
2. Discussion of Related Art
Agar (or agarose) which is a main polysaccharide constituting a red alga
TECHNICAL FIELD
The instant invention relates to a method for the differential diagnosis of inflammatory bowel disease. In more detail, the instant invention relates to a method for the differential diagnosis between ulcerative colitis and Crohn's disease in a patient with inflammatory bowel
FIELD OF THE INVENTION
The present invention relates to novel method for designing therapeutic polypeptides for treatment of inflammatory diseases.
BACKGROUND
Although cellular receptors for immunoglobulins were first identified nearly 40 years ago, their central role in the immune response was only
This application is filed under 35 U.S.C. .sctn.371 from International Patent Application No. PCT/JP94/00352, filed Mar. 4, 1994.
FIELD OF THE INVENTION
The present invention relates to the method for preparing Lewis-related compounds, especially Lewis x (Le.sup.x) and Lewis a (Le.sup.a) as well as
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention provides methods of treatment and prevention of selectin-dependent acute lung injury and diseases which result from selectin-dependent acute lung injury by administration of a sulfatide. The present invention also provides
TECHNICAL FIELD
The present invention relates to an anti-inflammatory agent, antiallergic agent, immunomodulator, cell differentiation inducer, apoptosis inducer, and a keratan sulfate oligosaccharide which is useful as an active ingredient of these pharmaceuticals.
BACKGROUND ART
Keratan sulfate is
TECHNICAL FIELD
The present invention relates to an anti-inflammatory agent, antiallergic agent, immunomodulator, cell differentiation inducer, apoptosis inducer, and a keratan sulfate oligosaccharide which is useful as an active ingredient of these pharmaceuticals.
BACKGROUND ART
Keratan sulfate is
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of PCT International Patent Application No. PCT/EP2004/052076, filed on Sep. 7, 2004, designating the United States of America, and published, in English, as PCT International Publication No. WO 2005/024418 A2 on Mar. 17,
PRIORITY CLAIM
This patent application claims priority to Indian Patent Application No. 939/DEP/2014, filed 1 Apr. 2014, the disclosure of which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
The present invention relates to polymeric biosurfactants isolated from two
FIELD OF INVENTION
The present invention is related to the field of cancer treatment. In one embodiment, the invention contemplates administering compounds to tumor lesions that induce local expression of .alpha.-gal epitopes within the tumor. In one embodiment, the administration induces regression
CROSS REFERENCE TO RELATED APPLICATIONS
This application is the U.S. National Phase Application of PCT/HR2014/000022, filed Jun. 11, 2014, which claims priority to Croatian Patent Application No. P20130568A, filed Jun. 20, 2013, the contents of such applications being incorporated by reference
TECHNICAL FIELD
The invention relates to agents that inhibit the activation of Factor X, and thus are candidates for treatment or prevention of thrombosis. More specifically, the invention concerns agents that affect the normal glycosylation pattern of Factor X and thus diminish its conversion to
TECHNICAL FIELD
The invention relates to agents that inhibit the activation of Factor X, and thus are candidates for treatment or prevention of thrombosis. More specifically, the invention concerns agents that affect the normal glycosylation pattern of Factor X and thus diminish its conversion to